Clik here to view.
Study Suggests Insulin Degludec Could Rival Lantus
A study has shown that Novo Nordisk’s ultra-long-acting insulin degludec, a investigational basal insulin, can provide control of blood sugar in diabetics as good as rival drug Lantus from Sanofi,...
View ArticleClik here to view.
Novo Nordisk Files Insulin Drugs to Rival Sanofi’s Lantus in Europe
Novo Nordisk has filed two marketing authorisation applications for approval to the European Medical Agency for their ultra long-acting insulin Degludec and insulin combination analogue DegludecPlus....
View ArticleClik here to view.
Enlight Forms Two New Partnerships
Enlight Biosciences LLC announced yesterday that they have formed new partnerships with AstraZeneca and Novo Nordisk. As partners, AstraZeneca and Novo Nordisk will have the chance to collaborate and...
View ArticleClik here to view.
Novo Nordisk Increase Staff in Emerging Markets
Novo Nordisk has revealed plans to expand their treatment for diabetes in emerging markets by employing roughly 1,000 additional employees over the next two years. Some of the emerging markets that...
View ArticleClik here to view.
Tresiba and Ryzodeq Approved by EU Regulators
European regulators have approved Novo Nordisk’s Tresiba and Ryzodeg, which Novo hopes will challenge Sanofi’s Lantus, the largest selling insulin product globally. The European Commission have granted...
View ArticleClik here to view.
Novo Nordisk’s Novoeight Drug Approved by FDA
Novo Nordisk has received approval from US regulatory body, the Food and Drug Administration (FDA) for their haemophilia A drug. The regulatory board have approved the Novo Nordisk’s Biologics License...
View ArticleClik here to view.
Novo Nordisk Announce 750 Million Kroner Investment in R&D Lab
Novo Nordisk has confirmed that they are investing around 750 million kroner (roughly equivalent to $130 million) on new diabetes laboratories at the R&D campus in Måløv, Denmark. Construction of...
View Article
